Phase I clinical trials. This Journal of Hematology & Oncology and Experimental Hematology & Oncology series invites submissions for the collection of research, review, and correspondence articles dedicated to Phase I clinical trials in the fields of either oncology or hematology.Join us in shaping the future of early-phase clinical research and accelerating the translation of promising ...

Citation Impact 2023 Journal Impact Factor: 29.9 5-year Journal Impact Factor: 27.1 Source Normalized Impact per Paper (SNIP): 4.489 SCImago Journal Rank (SJR): 7.522

Preparing main manuscript text Back to top. Quick points: Use double line spacing; Include line and page numbering; Use SI units: Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion to PDF

Journal of Hematology & Oncology operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate …

Journal of Hematology & Oncology strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files whenever possible.

5 天之前 · Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells. Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may be beneficial for cancer treatment.

2024年11月9日 · Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients with cancer harbor RAS mutations, which are typically associated with poor clinical outcomes. Over the past four decades, KRAS has long been considered an undruggable target due to the absence of suitable small-molecule binding …

Citation Impact 2023 Journal Impact Factor: 29.9 5-year Journal Impact Factor: 27.1 Source Normalized Impact per Paper (SNIP): 4.489 SCImago Journal Rank (SJR): 7.522

Citation Impact 2023 Journal Impact Factor: 29.9 5-year Journal Impact Factor: 27.1 Source Normalized Impact per Paper (SNIP): 4.489 SCImago Journal Rank (SJR): 7.522

2025年1月13日 · The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between cancer cells and the TME is crucial in …